October 22, 2016—Dr. Mikael von Euler will present data from Aprea Therapeutics’ Phase Ib study in high-grade serous ovarian cancer at the 7th International Mutant p53 Workshop in Melbourne, Australia. This oral presentation is scheduled for 11:35 AM on Friday October 28, 2016 as part of Session 11: Mutant p53 therapies.

Presentation title: PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC)